MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Sponsored by Funding for this supplement provided by Medtronic
Durability and Hemodynamics: The New Frontier in TAVR
A surgeon's perspective on how device attributes can improve these factors to facilitate good outcomes as the TAVR treatment population expands.
By Daniel O'Hair, MD
Evident Vascular Receives Financing for IVUS Platform Development
October 17, 2023—Evident Vascular, Inc., medical technology startup, announced that it has launched with a $35 million Series A financing from Vensana Capital.
TAV-in-TAV: Future Considerations for Intermediate- and Low-Risk Patients
Challenges to the transcatheter management of severe aortic stenosis across a lifetime.
By Akshay Kamath, MD; Shravan Rao, MD; Brett Sheridan, MD; Christian Spies, MD; and David Daniels, MD
A New Analysis of the COURAGE Trial
Experts weigh in with their opinions of a new analysis looking at crossover patients.
With John Spertus, MD, MPH, FACC, FAHA; William Fearon, MD; and Ralph G. Brindis, MD, MPH, MACC, FSCAI
SCAI Updates Consensus Guidelines on CCL Best Practices
April 28, 2021—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the release of an expert consensus statement providing guidance for contemporary cardiac catheterization lab (CCL) standards for cardiologists, catheterization lab directors, and hospital leadership.
FDA Approves Full Expansion of Thoratec's HeartMate III IDE Trial
April 2, 2015—Thoratec Corporation announced that it received final approval from the US Food and Drug Administration (FDA) to broaden enrollment of the HeartMate III United States clinical trial of up to 1,028 patients in up to 60 sites. The approval was based on the FDA’s evaluation of safety data from the first 10 HeartMate III implantations performed in recent months during a limited enrollment phase at five sites.
CMS MEDCAC Panel Reviews Evidence for Hospital and Heart Team Requirements for TAVR Programs
July 30, 2018—The Centers for Medicare & Medicaid Services (CMS) convened a panel of the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) on July 25 to seek recommendations regarding procedural volume requirements for hospitals and heart team members to begin and maintain transcatheter aortic valve replacement (TAVR) programs.
FDA Clears HeartFlow's FFRCT Technology
December 1, 2014—HeartFlow Inc. announced that it received de novo clearance from the US Food and Drug Administration (FDA) for its mathematically computed fractional flow reserve (FFRCT) technology, a noninvasive imaging technology for coronary artery disease that offers insight on both the extent of blockages and whether they are impacting blood flow.
An Interview With John Spertus, MD
The Clinical Director of Outcomes Research at Saint Luke's Mid America Heart Institute discusses the importance of measuring outcomes, as well as the many benefits of creating and implementing risk models to support a personalized approach to providing health care.
Concepts in PCI
By Ted E. Feldman, MD, FESC, FACC, FSCAI
